Research from Redeye, Redeye AB

Redeye

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen). 

Expertise in Denmark, Finland, Norway and Sweden.

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye leaves a comment following Alzinova’s announcement of the preliminary outcome of its SEK50.1m rights issue.</li><li>The rights issue was subscribed to 80%, in line with previously communicated commitments.</li><li>While a fully subscribed transaction would have been preferable, the outcome secures the necessary capital base and provides the company with an extended financial runway as it continues preparations for phase II and ongoing partnership discussions.</li></ul>

Redeye leaves a comment following Alzinova’s announcement of the preliminary outcome of its SEK50.1m rights issue.The rights issue was subscribed to 80%, in line with previously communicated commitments.While a fully subscribed transaction would have been preferable, the outcome secures the necessary capital base and provides the company with an extended financial runway as it continues preparations for phase II and ongoing partnership discussions.

Alzinova

Alzinova: Rights issue outcome